Reports of Biochemistry
and Molecular Biology
Sat, Apr 20, 2024
[Archive]
Volume 11, Issue 3 (Vol.11 No.3 Oct 2022)
rbmb.net 2022, 11(3): 440-449 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Davodian A, Foroughi K, Atashi A, Soleimani M. Synergistic Anti-Cancer Activity of the Combination of 1,25-Dihydroxyvitamin D3 and Retinoic Acid in U937 Cell Line. rbmb.net 2022; 11 (3) :440-449
URL: http://rbmb.net/article-1-927-en.html
URL: http://rbmb.net/article-1-927-en.html
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran & Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract: (1289 Views)
Background: MicroRNA is a form of non-coding RNAs that able to regulate gene expression. miR-424 is one of the members of the regulatory family, which plays an important role in the proliferation and differentiation of myeloid cells. Epigenetic changes can change the level of miR-424 under environmental factors. Therefore, the level of expression of miR-424 in U937 cells of the myeloid line was evaluated in this research under the influence of vitamin D3 (VitD3) and retinoic acid (RA).
Methods: In this study, U937 cells were cultured in the presence of VitD3, and RA to evaluate cell proliferation, viability via the trypan blue exclusion test, and expression level of miR-424 by real-time PCR at specific times.
Results: Cell proliferation has shown a significant decrease in the RA group versus other groups during incubation times (P < 0.05). In VitD3 group, there was a significant increase in cell proliferation after 24- and 48-hours incubation periods versus other groups. In the VitD3 and RA groups, the increase of cell proliferation caused the downregulation of miR-424. In addition, the upregulation of VitD3 group and downregulation of the RA group were significant versus the control group (P < 0.05).
Conclusions: We concluded that the expression level of miR-424 was critically affected in the dose- and time-dependent of RA and VitD3 treatment in the U937 cell line. Treatment with VitD3 decreased the expression of miR-424 and RA treatment increase miR-424 expression level in physiological doses.
Methods: In this study, U937 cells were cultured in the presence of VitD3, and RA to evaluate cell proliferation, viability via the trypan blue exclusion test, and expression level of miR-424 by real-time PCR at specific times.
Results: Cell proliferation has shown a significant decrease in the RA group versus other groups during incubation times (P < 0.05). In VitD3 group, there was a significant increase in cell proliferation after 24- and 48-hours incubation periods versus other groups. In the VitD3 and RA groups, the increase of cell proliferation caused the downregulation of miR-424. In addition, the upregulation of VitD3 group and downregulation of the RA group were significant versus the control group (P < 0.05).
Conclusions: We concluded that the expression level of miR-424 was critically affected in the dose- and time-dependent of RA and VitD3 treatment in the U937 cell line. Treatment with VitD3 decreased the expression of miR-424 and RA treatment increase miR-424 expression level in physiological doses.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2022/04/25 | Accepted: 2022/05/8 | Published: 2022/12/31
Received: 2022/04/25 | Accepted: 2022/05/8 | Published: 2022/12/31
References
1. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome res. 2009;19(1):92-105. [DOI:10.1101/gr.082701.108] [PMID] [PMCID]
2. Esteller M. Non-coding RNAs in human disease. Natu Rev Gen. 2011;12:861-74. [DOI:10.1038/nrg3074] [PMID]
3. Hamam D, Ali D, Kassem M, Aldahmash A, Alajez NM. microRNAs as regulators of adipogenic differentiation of mesenchymal stem cells. Stem Cells Dev. 2015;24(4):417-25. [DOI:10.1089/scd.2014.0331] [PMID] [PMCID]
4. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21(3):470-9. [DOI:10.1016/j.ceb.2009.03.002] [PMID]
5. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467(7311):86-90. [DOI:10.1038/nature09284] [PMID]
6. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81(2):103-22. [DOI:10.1016/j.critrevonc.2011.03.010] [PMID]
7. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, et al. MicroRNAs and cancer: Current state and future perspectives in urologic oncology. Urol Oncol. 2010;28(1):4-13. [DOI:10.1016/j.urolonc.2008.10.021] [PMID]
8. Liu P, Zhao H, Wang R, Wang P, Tao Z, Gao L, et al. MicroRNA-424 protects against focal cerebral ischemia and reperfusion injury in mice by suppressing oxidative stress. Stroke. 2015;46(2):513-9. [DOI:10.1161/STROKEAHA.114.007482] [PMID]
9. Zhao H, Wang J, Gao L, Wang R, Liu X, Gao Z, et al. MiRNA-424 Protects Against Permanent Focal Cerebral Ischemia Injury in Mice Involving Suppressing Microglia Activation. Stroke. 2013;44(6):1706-13. [DOI:10.1161/STROKEAHA.111.000504] [PMID]
10. Li L, Qi Q, Luo J, Huang S, Ling Z, Gao M, et al. FOXO1-suppressed miR-424 regulates the proliferation and osteogenic differentiation of MSCs by targeting FGF2 under oxidative stress. Sci Rep. 2017;10;7:42331. [DOI:10.1038/srep42331] [PMID] [PMCID]
11. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004;23(2):605-11. [DOI:10.1038/sj.onc.1207069] [PMID]
12. Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol. 2009;21(6):688-92. [DOI:10.1097/MEG.0b013e328306a3a2] [PMID]
13. Iwasaki H, Akashi K. Hematopoietic developmental pathways: on cellular basis. Oncogene. 2007;26:6687-96. [DOI:10.1038/sj.onc.1210754] [PMID]
14. Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011;47(8):1127-37. [DOI:10.1016/j.ejca.2011.02.008] [PMID]
15. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(8):631. [DOI:10.1038/nrg1415]
16. Taylor GA, Mazhindu HN, Findlay JBC, Peacock M. Purification of vitamin D binding protein from human plasma using high performance liquid chromatography. Clin Chim Acta. 1986;155(1):31-41. [DOI:10.1016/0009-8981(86)90096-3] [PMID]
17. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983;57(6):1308-10. [DOI:10.1210/jcem-57-6-1308] [PMID]
18. Bhalla AK, Amento EP, Krane SM. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: Inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol.1986;98(2):311-22. [DOI:10.1016/0008-8749(86)90291-1] [PMID]
19. Amento EP, Bhalla AK, Kurnick JT, Kradin RL, Clemens TL, Holick SA, et al. 1 alpha,25-dihydroxyvitamin D3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T lymphocytes, augments production of the monokine, mononuclear cell factor. J Clin Invest. 1984;73(3):731-9. [DOI:10.1172/JCI111266] [PMID] [PMCID]
20. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA. 1980;77(5):2936-40. [DOI:10.1073/pnas.77.5.2936] [PMID] [PMCID]
21. Goodman DS. Vitamin A and retinoids in health and disease. N Engl J Med. 1984;310(16):1023-31. [DOI:10.1056/NEJM198404193101605] [PMID]
22. Spom MB, Roberts AB. Role of Retinoids in Differentiation and Carcinogenesis. Cancer Res. 1983;43(7):3034-40.
23. Thill M, Woeste A, Reichert K, Fischer D, Rody A, Friedrich M, et al. Vitamin D Inhibits Ovarian Cancer Cell Line Proliferation in Combination with Celecoxib and Suppresses Cyclooxygenase-2 Expression. Anticancer Res. 2015;35(2):1197-203.
24. Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol.2015;111(1): A3.B.1-A3.B.3. [DOI:10.1002/0471142735.ima03bs111] [PMID] [PMCID]
25. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45. [DOI:10.1093/nar/29.9.e45] [PMID] [PMCID]
26. Stein LD. End of the beginning. Nature. 2004;431:915-916. [DOI:10.1038/431915a] [PMID]
27. Montano M. MicroRNAs: miRRORS of health and disease. Transl research. 2011;157(4):157-62. [DOI:10.1016/j.trsl.2011.02.001] [PMID] [PMCID]
28. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. RNA. 2003;9(2):175-9. [DOI:10.1261/rna.2146903] [PMID] [PMCID]
29. Bollag WB, Ducote J, Harmon CS. Biphasic effect of 1,25-dihydroxyvitamin D3 on primary mouse epidermal keratinocyte proliferation. J Cell Physiol. 1995;163(2):248-56. [DOI:10.1002/jcp.1041630205] [PMID]
30. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012;13(4):271-82. [DOI:10.1038/nrg3162] [PMID]
31. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-74. [DOI:10.1016/j.cell.2011.02.013] [PMID]
32. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-72.
https://doi.org/10.1182/blood.V72.2.567.bloodjournal722567 [DOI:10.1182/blood.V72.2.567.567] [PMID]
33. Chomienne C, Ballerini P, Balitrand N, Huang ME, Krawice I, Castaigne S, et al. The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. Leukemia. 1990;4(12):802-7.
34. Grenier E, Maupas FS, Beaulieu J-F, Seidman E, Delvin E, Sane A, et al. Effect of retinoic acid on cell proliferation and differentiation as well as on lipid synthesis, lipoprotein secretion, and apolipoprotein biogenesis. Am J Physiol Gastrointest Liver Physiol. 2007;293(6):G1178-89. [DOI:10.1152/ajpgi.00295.2007] [PMID]
35. Najafzadeh N, Abbasi A, Mazani M, Amani M. Effects of all Trans Retinoic Acid Combined with Cisplatin on Survival of Gastric Cancer Cell Line (AGS). Avicenna J Clin Med 2013;20(3):207-214.
36. Rosa A, Ballarino M, Sorrentino A, Sthandier O, De Angelis FG, Marchioni M, et al. The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. Proc Natl Acad Sci USA. 2007;104(50):19849-54. [DOI:10.1073/pnas.0706963104] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
